Skip to main content
OpenTrials
Completed

NCT Number: NCT04670198

A Psychosocial Education Programme for Young People With Type 1 Diabetes - the Youth Empowerment Skills (YES)

Adolescence is a period of intense physiological, psychological and social change. It can be a challenging period for young people with Type 1 diabetes and is associated with worsening blood sugar control and care disengagement. The investigators have co-designed with young people a psychologically modelled educational programme - Youth Empowerment Skills (YES), which aims to facilitate a positive adaption to living with diabetes while improving knowledge and self-management behaviours. Integrated programme components include social and peer-based learning, immersive simulations, and an outreach youth worker.

The aim of this study is to test the feasibility of the YES programme (acceptance, implementability, recruitment and completion), and estimate its efficacy in relation to metabolic and psychosocial outcomes. The investigators will recruit young people with Type 1 diabetes and conduct a feasibility randomised controlled trial (waiting-list design) with integrated process evaluation. Sixty young people will be randomised to either YES intervention or waiting-list control and evaluate outcomes at 6-months; at this point the waiting list participants will be offered the YES intervention with further follow-up at 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Loading trial locations.

About this study

The study has been designed as a feasibility study with an integrated process evaluation following MRC guidance (Craig et al., 2008; Moore et al., 2015). The process evaluation data collection has been modelled on the COM_B and the Behaviour Change Wheel framework (BCW) frameworks (Michie et al., 2014; Barker et al., 2016) addressing: policy context; intervention functions; target behaviours; and outcomes. As part of the process evaluation the investigators will also use Consolidated Framework for Implementation Research (CFIR) to study how the programme can be optimally embedded within routine diabetes care, and to optimise the design of a subsequent trial (Murray et al., 2010). The investigators will conduct a feasibility randomised controlled trial (waiting-list design) with integrated process evaluation designed following the Medical Research Council's (MRC) Complex Intervention Evaluation Framework (Craig et al., 2008). Sixty young people will be randomised to either YES intervention or waiting-list control and evaluate outcomes at 6-months; at this point the waiting list participants will be offered the YES intervention with further follow-up at 12 months.

The proportion of patients achieving the progression criteria and the target reduction in glycated haemoglobin (HbA1c) from baseline to follow-up (6 and 12 months) will be estimated in both intervention and waiting list control groups. The investigators will also estimate the standard deviation (SD) of the mean difference between the intervention and waiting list control groups in HbA1c at 6 and 12 months. These statistics will help to inform the sample size calculation of a larger trial.

The process evaluation will consider the setting, implementation, and mechanisms of action of the programme to support interpretation of the outcomes. The process evaluation uses a standardised taxonomy for understanding implementation (Julious, 2005; Proctor et al., 2011), and will assess: the reach, fidelity and receipt of the programme; acceptability, appropriateness and feasibility; unintended consequences; potential sustainability; and implementation costs and strategies. In addition, potential mechanisms of action will be elicited, including changes in behaviours, and how they relate to programme delivery and outcomes.

The investigators will use a mixed-method approach with validated implementation outcome surveys (Powell et al., 2015) and one-to-one interviews with young people, their relatives and healthcare professionals. The data collection tools and analytic models have been designed with reference to the BCW (Michie et al., 2014) and to provide the data for CFIR analysis, considering the barriers and facilitators to the intervention. To ensure relevance and feasibility, the data collection procedures will be refined with the study patient and public involvement groups. Data collection will be conducted at multiple time points to provide opportunities for data triangulation and subsequent theory generation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Type 1 diabetes
  • Sub-optimal glycaemic control (HbA1c 8.5%)
  • No current or planned attendance at other structured education programmes

Exclusion criteria

  • Severe, physical/mental illness
  • Pregnancy
  • Unstable retinopathy
  • Significant learning difficulties

Treatment and study plan

Youth Empowerment Skills

Behavioral

The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional

Waiting-list control

Behavioral

Usual care for 6 months, followed by the YES programme.

Primary outcomes

  1. Glycated haemoglobin (HbA1c)

    Time frame: Baseline, 6 months, 12 months

    HbA1c will be used to measure:

    • the number of participants achieving clinically significant reductions of 5.5mmol/mol or more and mean differences between groups over time
    • the standard deviation (SD) of the mean difference between the intervention and control group in HbA1c at 6 months; for the control group the SD of the mean difference between HbA1c at 12 months and pre-exposure (phase 2) and for the phase 1 intervention group the SD of the mean HbA1c difference between post (6 and 12 months) and pre-exposure.

Secondary outcomes

  1. Frequency of blood glucose monitoring

    Time frame: Baseline, 6 months, 12 months

    Participants' glucose meters will be downloaded to assess the number of participants with 20% increase in frequency of glucose monitoring between pre- and post-intervention exposure, and any difference between intervention and control groups at 6 months.

  2. Insulin adherence

    Time frame: Baseline, 6 months, 12 months

    Insulin adherence will be measured by self-report scale to assess the number of participants reporting a change in insulin adherence between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months.

    Maximum score is 10 and minimum score is 2. Higher scores indicate better adherence.

  3. Self-Management of Diabetes in Adolescence Scale (SMOD-A)

    Time frame: Baseline, 6 months, 12 months

    The SMOD-A will be used to assess any change in self-management of diabetes between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months. This consists of five subscales.

    Subscale 1: Collaboration with Parents. The range of scores is 0 to 39. Higher scores indicate more collaboration.

    Subscale 2: Diabetes Care Activities. The range it 0 to 45. Higher scores indicate more/better performance of these diabetes tasks.

    Subscale 3: Diabetes Problem-Solving. Range of scores is 0 to 21. Higher scores indicate better/more problem-solving.

    Subscale 4: Diabetes Communication. The range of scores is 0 to 30. Higher scores indicate better/more communication.

    Subscale 5: Goals. The range of scores is 0 to 21. Higher scores indicate more goals.

  4. Confidence in Diabetes Self-Care Scale (CDSS)

    Time frame: Baseline, 6 months, 12 months

    The CDSS will be used to measure any change in confidence in diabetes self-care between pre-and post-intervention exposure, and between intervention and control groups at 6 months. Maximum value is 100, minimum value is 20. Higher score means more confidence.

  5. Diabetes Quality of Life Instrument (DQOL) (adapted for youth)

    Time frame: Baseline, 6 months, 12 months

    The DQOL will be used to assess any change in quality of life between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months.

    DQOL has 3 subscales:

    Subscale 1: Impact of diabetes. Maximum value is 120. Minimum value is 24. Higher scores indicate more impact of diabetes on quality of life.

    Sunscale 2: Worries about diabetes. Maximum score is 55. Minimum score is 11. Higher scores mean more worries.

    Subscale 3: Satisfaction with life. Maximum score 85. Minimum score 5. Higher score means more satisfied.

  6. Brief Illness Perception Questionnaire (IPQ-B)

    Time frame: Baseline, 6 months, 12 months

    The IPQ-B will be used to measure any change in diabetes perception between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months. Each of the eight dimensions measured uses a maximum score of 10 and a minimum score of 0. A higher score indicates more severe perception of illness.

  7. Emergency care events

    Time frame: Baseline, 6 months, 12 months

    The number of ambulance call-outs, Accident & Emergency attendance and hospitalisations will be taken from hospital records to assess any change in number of events between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months.

  8. Hypoglycaemia and severe hypoglycaemic events

    Time frame: Baseline, 6 months, 12 months

    Hypoglycaemia is defined as blood glucose 3.5 mmol/L and severe hypoglycaemic events are defined as requiring 3rd party assistance. The number of events will be taken from hospital records to assess any change in hypoglycaemia and severe hypoglycaemic events between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months.

  9. Weight

    Time frame: Baseline, 6 months, 12 months

    Participants will be weighed at baseline, 6 and 12 months to assess any change in weight between pre- and post-intervention exposure, and the difference between intervention and control groups at 6 months.

  10. Intervention Appropriateness Measure (IAM)

    Time frame: Within 3 months of intervention

    Intervention Appropriateness Measure will be used to assess the appropriateness of the intervention. It is a four-item questionnaire measuring implementation outcomes. Score values range from 1 to 5. The higher the score the more appropriate the intervention.

  11. Feasibility of Intervention Measure (FIM)

    Time frame: Within 3 months of intervention

    Feasibility of Intervention Measure will be used to assess the feasibility of the intervention. It is a four-item questionnaire measuring implementation outcomes. Score values range from 1 to 5. The higher the score the more feasible the intervention.

  12. Acceptability of Intervention Measure (AIM)

    Time frame: Within 3 months of intervention

    Acceptability of Intervention Measure will be used to assess the acceptability of the intervention. It is a four-item questionnaire measuring implementation outcomes. Score values range from 1 to 5. The higher the score the more acceptable the intervention.

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Diabetes UK
  • Guy's and St Thomas' NHS Foundation Trust

Registry information

Official study title

A Randomised Waiting-list Feasibility Study and Process Evaluation of a Psychosocial Education Programme for Young People With Type 1 Diabetes - the Youth Empowerment Skills (YES)

Acronym: YES

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Dec 17, 2020
Registry last updated
Oct 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.